Inflammatory Bowel Disease Treatment Market (By Type: Crohn's Disease, Ulcerative Colitis; By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors; By Route of Administration: Oral, Injectable; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Inflammatory Bowel Disease Treatment Market, By Type

7.1.  Inflammatory Bowel Disease Treatment Market, by Type, 2021-2030

7.1.1.    Crohn's Disease

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Ulcerative Colitis

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Inflammatory Bowel Disease Treatment Market, By Drug Class

8.1.  Inflammatory Bowel Disease Treatment Market, by Drug Class, 2021-2030

8.1.1.    Aminosalicylates

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Corticosteroids

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    TNF inhibitors

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    IL inhibitors

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Anti-integrin

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    JAK inhibitors

8.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

9.1.  Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2021-2030

9.1.1.    Hospital Pharmacy

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Retail Pharmacy

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Online Pharmacy

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

10.1.        Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2021-2030

10.1.1.  Oral

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Injectable

10.1.2.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Inflammatory Bowel Disease Treatment Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Type (2017-2030)

11.1.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

11.1.3.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4.  Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Type (2017-2030)

11.2.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

11.2.3.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4.  Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Type (2017-2030)

11.3.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

11.3.3.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4.  Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Type (2017-2030)

11.4.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

11.4.3.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4.  Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Type (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Type (2017-2030)

11.5.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

11.5.3.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4.  Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Type (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 12.  Company Profiles

12.1.              AbbVie Inc.

12.1.1.  Company Overview

12.1.2.  Type Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Biogen

12.2.1.  Company Overview

12.2.2.  Type Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Johnson & Johnson Services, Inc.

12.3.1.  Company Overview

12.3.2.  Type Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Amgen Inc.

12.4.1.  Company Overview

12.4.2.  Type Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              UCB S.A.

12.5.1.  Company Overview

12.5.2.  Type Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Novartis AG

12.6.1.  Company Overview

12.6.2.  Type Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Takeda Pharmaceutical Company Limited

12.7.1.  Company Overview

12.7.2.  Type Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Merck & Co., Inc.

12.8.1.  Company Overview

12.8.2.  Type Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Pfizer Inc.

12.9.1.  Company Overview

12.9.2.  Type Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Lilly

12.10.1.               Company Overview

12.10.2.               Type Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms